Four years ago, Indian regulators suspended licenses on 3 vaccine manufacturing facilities due to quality issues. The suspensions resulted in vaccine shortages to great hue and outcry by the populace. The government will now invest $37 M in plant upgrades to cGMP.
India plans $37m investment in vaccine cGMP compliance.
The DPT vaccine facility in Coonoor and BCG vaccine facility in Chennai will receive the bulk of the new investment. Upgrades are nearly complete now at the third facility in Kasauli. The government wants to see the improvement in quality and to boost vaccine output.
HLL, a company best known for producing condoms, is responsible for making the upgrades. Now, that's what I call real prophylaxis.
Posted by Bruce Lehr May 2nd 2012.
Comments